Jaguar Health Stock News

With 2021 coming to an end, which penny stocks are you watching? The post Top Penny Stocks to Add to Your Watchlist As 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by over 8% this week. This is why it happened.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S

During the last session, Jaguar Health Inc. (NASDAQ:JAGX)s traded shares were 0.8 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stocks price was $1.38, reflecting an intraday loss of -3.50% or -$0.05. The 52-week high for the JAGX share is $13.41, that puts it down During The Past Six Months, Jaguar Health Inc. (NASDAQ: JAGX) Shares Took An -71.25% Jump. Here Is What We Should Expect Read More »

In the last trading session, 1.4 million shares of the Jaguar Health Inc. (NASDAQ:JAGX) were traded, and its beta was 1.57. Most recently the companys share price was $1.38, and it changed around -$0.13 or -8.61% from the last close, which brings the market valuation of the company to $61.60M. JAGX currently trades at a Jaguar Health Inc. (NASDAQ: JAGX): A Business Review And Growth Forecast Read More »

Jaguar Health (NASDAQ:JAGX) issued its earnings results on Wednesday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09), MarketWatch Earnings reports. Jaguar Health had a negative net margin of 612.54% and a negative return on equity of 205.92%. During the same quarter last year, []

Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial inc

(PR-inside.com) Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention of chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane.1 These therapies are known to cause CID in up to 80% of breast cancer patients, reaching grade 3 (requiring hospitalization) in 8-12% of patients.2-5 CID can have a negative impact on quality of life, particularly when it persists through much of the course of ..

Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medicationSAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2021 Results - Earnings Call Transcript

Jaguar Health (NASDAQ:JAGX) reported its Q3 earnings results on Wednesday, November 17, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcastSAN FRANCISCO,

Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Wednesday, 2021-11-17. Here's what investors need to know before the announcement.